Fig. 3From: Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experienceNRS response follow-up. Abbreviations according to Farrar et al. 2008. CID: Clinically important difference (> = 30% improvement on the NRS score) / MCID: minimal clinically important difference (> = 20% improvement on the NRS score) / no-MCID: < 20% improvement on the NRS score [21]. The 29 patients with deviating data collection have not been considered for response follow-upBack to article page